Rayner Intraocular Lenses Limited
$421.7K 2,145 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Almatica Pharma LLC
Almatica Pharma LLC reported $421,906.73 across General Payments, Research, and Ownership to 15,812 physicians and teaching hospitals across 15,812 transactions.
- $421.9K Above-median payer
- All-tracks total
- 15,812 Top 10% volume
- Transactions
- 15,812 Top 10% reach
- Recipients
- +$151.0K
- General Payments vs PY2023
Almatica Pharma LLC reported $421,906.73 across all CMS Open Payments tracks (General + Research + Ownership) to 15,812 physicians and teaching hospitals in Program Year 2024 - ranking #804 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $421,906.73, averaging $26.68 per recipient.
How Almatica Pharma LLC's $421.9K all-tracks total breaks down
Almatica Pharma LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
63/100
Total payments
F
14/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer almatica-pharma-llc Almatica Pharma LLC
$421.9K · #804/1,925 · 0.0% industry · PY2024
- TOT $421.9K
- RANK #804
- SHARE 0.0%
- TXN 15,812
- RCP 15,812
- CAT 3
- GEN $421.9K
- ΔGEN +$151.0K
- TOP1 7.7%
- PY 2024
Volume peers
Nearest volume peer: Rayner Intraocular Lenses Limited ($421.7K)
Almatica Pharma LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Almatica Pharma LLC's CMS-reported General Payments increased by $151.0K (+55.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ALMATICA PHARMA LLCPY2023: ALMATICA PHARMA LLCPY2024: Almatica Pharma LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $270,922.03
- PY2024
- $421,906.73
What the Data Shows for Almatica Pharma LLC
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Almatica Pharma LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
15,571 transactions worth $297.7K make "Food and Beverage" the top general-payment category in the 3-category breakdown below, 70.6% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 3 types of general payments, Almatica Pharma LLC's largest category was "Food and Beverage" at $297.7K - 70.6% of General Payments.
How Almatica Pharma LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $297.7K | 15,571 | 70.6% |
| Compensation for Services Other Than Consulting | $122.5K | 237 | 29.0% |
| Honoraria | $1.6K | 4 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $76,971.34 (18.2%) of $421,906.73 in this company's General Payments records across 5,997 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Almatica Pharma LLC
The five named recipients with the highest reported General Payments from this company
- 1
Gary Leonhardt
$32,549.00 across 44 reported transactions
- 2
Idan Sharon
$17,982.41 across 48 reported transactions
- 3
Cristina D Meehan
$10,877.16 across 37 reported transactions
- 4
Michael Banov
$8,359.96 across 17 reported transactions
- 5
Christopher Malsch
$7,202.81 across 20 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Almatica Pharma LLC ranks #804 of 1,925 by total payments (top 42% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,684 of 1,838 by HHI (bottom 8% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- ADC Therapeutics America, Inc. : $1.1M total payments, HHI 111
- Kyowa Kirin, Inc. : $2.5M total payments, HHI 111
- Xeris Pharmaceuticals, Inc. : $1.2M total payments, HHI 110
- Mallinckrodt Hospital Products Inc. : $7.6M total payments, HHI 109
- Lexicon Pharmaceuticals, Inc. : $2.5M total payments, HHI 108
- Nevro Corp. : $2.5M total payments, HHI 107
- Almatica Pharma LLC (this company) : $421.9K total payments, HHI 106
- Vifor Pharma, Inc. : $368.6K total payments, HHI 106
- Grifols USA, LLC : $2.0M total payments, HHI 105
- Neurelis, Inc. : $1.9M total payments, HHI 104
- ACADIA Pharmaceuticals Inc : $2.6M total payments, HHI 102
- Biotronik Inc. : $2.4M total payments, HHI 102
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Almatica Pharma LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Almatica Pharma LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Almatica Pharma LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Bio-Rad Laboratories, Inc.
$421.2K 810 recipients
Compare payment profiles
Cepheid
$423.4K 260 recipients
Compare payment profiles
CeQur Corporation
$420.1K 9,797 recipients
Compare payment profiles
WyCo Surgical Distribution LLC
$418.5K 0 recipients
Compare payment profiles
Incline Medical
$417.4K 0 recipients
Compare payment profiles
Put this to use
Almatica Pharma LLC ranks #804 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Almatica Pharma LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.